All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1…
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus…
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate…